{"id":"ca125-guided-strategy","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL6033602","moleculeType":null,"molecularWeight":"527.58"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a clinical management strategy rather than a drug itself, wherein CA125 (cancer antigen 125) levels are monitored during and after treatment to guide therapeutic decisions, assess treatment response, and detect recurrence. The approach aims to optimize chemotherapy timing and intensity based on CA125 kinetics, potentially improving outcomes while minimizing unnecessary treatment exposure.","oneSentence":"CA125 guided strategy uses serial measurement of the tumor marker CA125 to inform treatment decisions and monitoring in ovarian cancer patients.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:16:57.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Ovarian cancer treatment monitoring and management"}]},"trialDetails":[{"nctId":"NCT02643147","phase":"PHASE4","title":"Loop Diuretic Dosage in Patients With Acute Heart Failure and Renal Failure: Conventional Versus Carbohydrate Antigen 125-guided Therapy (IMPROVE-HF)","status":"COMPLETED","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2015-01","conditions":"Heart Failure","enrollment":170},{"nctId":"NCT02008110","phase":"PHASE4","title":"Carbohydrate Antigen 125-guided Therapy in Heart Failure","status":"COMPLETED","sponsor":"Fundación para la Investigación del Hospital Clínico de Valencia","startDate":"2011-12","conditions":"Heart Failure","enrollment":360}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Loop diuretic (Furosemide) dosage in CA125 ≤35 U/ml patients","Loop diuretic dosage (Furosemide) in CA125 >35 U/ml patients"],"phase":"marketed","status":"active","brandName":"CA125 guided strategy","genericName":"CA125 guided strategy","companyName":"Fundación para la Investigación del Hospital Clínico de Valencia","companyId":"fundaci-n-para-la-investigaci-n-del-hospital-cl-nico-de-valencia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CA125 guided strategy uses serial measurement of the tumor marker CA125 to inform treatment decisions and monitoring in ovarian cancer patients. Used for Ovarian cancer treatment monitoring and management.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}